Correlation Between Triglyceride Glucose Index and Residual SYNTAX Score in STEMI Patients Undergoing PPCI
Launched by ASSIUT UNIVERSITY · Oct 12, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how two specific measures—triglyceride glucose (TyG) index and residual SYNTAX score (RSS)—relate to each other in patients who have experienced a heart attack known as STEMI (ST Elevation Myocardial Infarction) and are undergoing a procedure called primary percutaneous coronary intervention (PPCI) to open blocked arteries. The study aims to see how these measures affect heart recovery three months after the procedure and to explore their impact on any major health complications during that time.
To participate in this trial, individuals must be between 18 and 80 years old and have been diagnosed with STEMI, making them eligible for the PPCI treatment. However, those who have previously undergone similar heart procedures, have serious health conditions that limit their life expectancy, or cannot provide consent will not be included. Participants can expect to have their blood tested and their heart function monitored, helping researchers learn how these measures influence recovery after a heart attack. This study is important as it may provide insights that improve treatment and outcomes for future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patient who are between 18 and 80 years old who present to our hospital (Assiut university heart hospital) with STEMI and eligible for primary PCI as treatment of choice according to guidelines, will be included in our study.
- Exclusion Criteria:
- • Patient who refuse to undergo revasculariztion using primary PCI.
- • Patient who will die before withdraw of laboratory blood sample.
- • Patient with previous PCI and/or CABG.
- • Patient with underlying co-morbidity with life expectancy less than 1 year (end stage liver disease, end stage renal disease on regular dialysis, active malignancy).
- • Patient with failed canalization of infarct related artery.
- • Patient referred to CABG after angiography.
- • Patient who is unconscious after cardiac arrest .
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Salwa Roshdy, Pro
Study Director
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported